Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 3.22B |
| Revenue (ttm) | 1.19M |
| Net Income (ttm) | -444.04M |
| Shares Out | 279.31M |
| EPS (ttm) | -1.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,302,150 |
| Open | 11.50 |
| Previous Close | 11.71 |
| Day's Range | 11.16 - 11.65 |
| 52-Week Range | 3.21 - 18.33 |
| Beta | 0.59 |
| Analysts | Strong Buy |
| Price Target | 25.64 (+122.18%) |
| Earnings Date | May 7, 2024 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combinat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for IOVA stock is "Strong Buy." The 12-month stock price forecast is $25.64, which is an increase of 122.18% from the latest price.
News
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileuce...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and deliver...
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclon...
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.
Shares of the biotechnology company are on pace for their best day since June 2016.
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA , Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ...
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering n...
Iovance (IOVA) stock price could rocket higher ahead of earnings
Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earning...
FDA Approves First Cellular Treatment For Advanced Melanoma
The Food and Drug Administration approved a groundbreaking cellular treatment Friday for two types of advanced melanoma aimed at combating tumor growth in adult patients with the skin cancer who have ...
US FDA grants accelerated approval for Iovance's skin cancer cell therapy
Iovance Biotherapeutics said on Friday the U.S. health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approve...
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance's AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are a...
3 Charts For Investors to Watch Thursday: GC Education, Iovance, Ethereum
Here's our daily look at three charts connected to recent news-driven price moves, with key technical levels to monitor.
Iovance stock drops 23% in premarket trades after it halts cancer drug trial
Iovance Biotherapeutics Inc.'s stock IOVA, +6.59% fell 22.6% in premarket trading on Wednesday after the cancer therapy company said the U.S. Food and Drug Administration placed a clinical hold on its...
Iovance's IOVA stock price suffers a harsh reversal: buy the dip?
Iovance Biotherapeutics (NASDAQ: IOVA) stock price suffered a harsh reversal on Wednesday after the company suffered a major setback. The stock, which has been in a strong uptrend, crashed by more tha...
Iovance Stock Plunges as FDA Puts Hold on Lung Cancer Study After Patient Death
The FDA places a clinical hold on Iovance's trial of a lung cancer therapy after the company reports a death potentially related to the treatment.
US FDA places clinical hold on Iovance's lung cancer treatment trial
Iovance Biotherapeutics said on Wednesday that the U.S. Food and Drug Administration has placed a clinical hold on its trial on a therapy for a type of lung cancer.
US FDA puts clinical hold on Iovance's cancer therapy trial
The U.S. health regulator has placed a clinical hold on Iovance Biotherapeutics' trial of its experimental cell therapy in lung cancer patients after a patient death, the company said on Wednesday, se...
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infi...
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer's (SITC) 38th Annual Meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...